Literature DB >> 18227384

Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression.

Andreas Goette1, Alicja Bukowska, Uwe Lendeckel, Michaela Erxleben, Matthias Hammwöhner, Denis Strugala, Jan Pfeiffenberger, Friedrich-Wilhelm Röhl, Christof Huth, Matthias P A Ebert, Helmut U Klein, Christoph Röcken.   

Abstract

BACKGROUND: Increased levels of inflammatory markers are predictors of thromboembolic events during atrial fibrillation (AF). Increased endocardial expression of adhesion molecules (ie, vascular cell adhesion molecule [VCAM] and intercellular adhesion molecule [ICAM]) could be an important link between initiation of inflammatory and prothrombogenic mechanisms responsible for thrombus development at the atrial endocardium (endocardial remodeling). METHODS AND
RESULTS: Tissue microarrays were used to screen right atrial tissue specimens obtained from 320 consecutive patients for differences in atrial expression of the prothrombogenic proteins VCAM-1, ICAM-1, thrombomodulin, plasminogen activator inhibitor-1, and von Willebrand factor. An in vitro organotypic human atrial tissue model and a pig model of rapid atrial pacing were used to determine the therapeutic impact of angiotensin II receptor blockade. Immunohistochemical analyses showed that all prothrombogenic proteins are expressed by endocardial cells. Using multivariable analysis, only the intensity of VCAM-1 expression was increased in patients with AF (P=0.03). Increased atrial VCAM-1 expression was confirmed by Western blotting in patients with persistent and paroxysmal AF (persistent AF 207+/-42% versus sinus rhythm 100+/-16%, P=0.028; paroxysmal AF 193+/-42%, P=0.024 versus sinus rhythm). In vitro pacing of ex vivo human atrial tissue slices confirmed that rapid activation causes VCAM-1 upregulation (mRNA and protein levels). Pacing-induced VCAM-1 expression was abolished by olmesartan. To confirm this finding in vivo, VCAM-1 expression was determined in 14 pigs after rapid atrial pacing (600 bpm). Atrial tachycardia caused an upregulation of VCAM-1 expression, which was prevented by irbesartan, consistent with the observed increase in plasma levels of angiotensin II. Alterations in the in vivo VCAM-1 expression were more pronounced in the left atrium (>5-fold compared with sham) than in the right atrium (3.5-fold compared with sham).
CONCLUSIONS: AF and rapid atrial pacing both increase endocardial VCAM-1 expression, which can be attenuated by angiotensin II receptor blockade. This provides evidence that angiotensin II plays a pathophysiological role in prothrombotic endocardial remodeling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18227384     DOI: 10.1161/CIRCULATIONAHA.107.730101

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  38 in total

Review 1.  Alterations in atrial perfusion during atrial fibrillation.

Authors:  Christina F Pacchia; Derek J Dosdall; Ravi Ranjan; Edward DiBella
Journal:  Exp Physiol       Date:  2014-07-25       Impact factor: 2.969

2.  Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation.

Authors:  Joachim R Ehrlich; Magdalena Kaluzny; Stefan Baumann; Ralf Lehmann; Stefan H Hohnloser
Journal:  Clin Res Cardiol       Date:  2011-07-03       Impact factor: 5.460

3.  Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men.

Authors:  A Bukowska; L Spiller; C Wolke; U Lendeckel; S Weinert; J Hoffmann; P Bornfleth; I Kutschka; A Gardemann; B Isermann; A Goette
Journal:  Exp Biol Med (Maywood)       Date:  2017-06-29

4.  LOWERING THE RISK FOR THROMBUS AND STROKE IN ATRIAL FIBRILLATION PATIENTS: Will Dabigatran Replace Warfarin?

Authors:  Alex Y Tan; Michael A Rosenberg
Journal:  Clin Med Rev Vasc Health       Date:  2013-06-20

Review 5.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 6.  Inflammation and the pathogenesis of atrial fibrillation.

Authors:  Yu-Feng Hu; Yi-Jen Chen; Yenn-Jiang Lin; Shih-Ann Chen
Journal:  Nat Rev Cardiol       Date:  2015-01-27       Impact factor: 32.419

7.  Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs.

Authors:  A Bukowska; M Hammwöhner; A Sixdorf; L Schild; I Wiswedel; F-W Röhl; C Wolke; U Lendeckel; C Aderkast; S Bochmann; R K Chilukoti; J Mostertz; P Bramlage; A Goette
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 8.  Atrial thrombogenesis in atrial fibrillation : Results from atrial fibrillation models and AF-patients.

Authors:  Alicja Bukowska; Matthias Hammwöhner; Domenico Corradi; Wisno Mahardhika; Andreas Goette
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-12-12

9.  Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation.

Authors:  Andreas Goette; Alessandra D'Alessandro; Alicja Bukowska; Siegfried Kropf; Christian Mewis; Christoph Stellbrink; Jürgen Tebbenjohanns; Christian Weiss; Uwe Lendeckel
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 10.  New drugs for atrial fibrillation.

Authors:  Matthias Hammwöhner; Jan Smid; Uwe Lendeckel; Andreas Goette
Journal:  J Interv Card Electrophysiol       Date:  2008-06-06       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.